THERAPY DOSSIER · th-8b920af21a10

AES16-2M, a synthetic pentapeptide (REGRT, 618 Da, purity >98%)

Biologic · AES16-2M, a synthetic pentapeptide (REGRT).

Evidence & regulatory context

Mechanism: AES16-2M, a synthetic pentapeptide (REGRT).
Target: Not recorded
Injury models: Wound
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30258088 ↗2018Reported benefit

ERK activating peptide, AES16-2M promotes wound healing through accelerating migration of keratinocytes.

MouseWoundBALB/c wild-type and BALB/c-nudeFemaleTopical gel applied to the wound0.5 microgram per wound in 50 microlitres of 20% Pluronic F…Applied to the wound area after punch wounding

Model: Acute full-thickness 10 mm diameter dorsal excisional punch wound under avertin anaesthesia; supporting in vitro HaCaT scratch and human dermal fibroblast transwell migration assays

Wound size decreased steadily with AES16-2M, significantly versus control peptide on days 2 to 8 in BALB/c wild-type mice and on days 2, 3 and 9 in BALB/c-nude mice. At day 4 the treated group showed multiple epithelial layers at the wound edge, increased granulation tissue, increased CD31 and a si…

Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…